Cargando…

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

BACKGROUND: Duloxetine and venlafaxine extended release (venlafaxine XR) are SNRIs indicated for the treatment of MDD. This study addresses whether duloxetine and venlafaxine XR are interchangeable in their patterns of use with patients who are depressed or are used more selectively based on treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Wenyu, Zhao, Yang, Robinson, Rebecca L, Swindle, Ralph W
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044657/ https://www.ncbi.nlm.nih.gov/pubmed/21281479 http://dx.doi.org/10.1186/1471-244X-11-19

Ejemplares similares

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom
por: Shi, Nianwen, et al.
Publicado: (2012)

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder
por: Sobocki, P, et al.
Publicado: (2008)

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons
por: Eckert, Laurent, et al.
Publicado: (2006)

Uncontrolled Self-Medication with Venlafaxine in a Patient with Major Depressive Disorder
por: Song, Ji-Hye, et al.
Publicado: (2011)

Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder
por: Tian, Yanghua, et al.
Publicado: (2016)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada, Eiji, et al.
Publicado: (2016)

Venlafaxine in the treatment of panic disorder
por: Katzman, Martin A, et al.
Publicado: (2007)

Pharmacy and Medical Costs Associated With Switching Between Venlafaxine and SSRI Antidepressant Therapy for the Treatment of Major Depressive Disorder
por: Khandker, Rezaul K., et al.
Publicado: (2008)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider, Miqdad, et al.
Publicado: (2017)

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
por: Lee, Min-Soo, et al.
Publicado: (2012)

Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder
por: Hosseini, Fatemeh, et al.
Publicado: (2015)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder
por: Aldosary, Fahad, et al.
Publicado: (2021)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004)

Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study
por: Maund, Emma, et al.
Publicado: (2014)

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
por: Manna, Chayan K., et al.
Publicado: (2023)

The role of duloxetine in the treatment of anxiety disorders
por: De Berardis, Domenico, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Norman, Trevor R, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Wright, Alan, et al.
Publicado: (2009)

Comparison of the efficacy of venlafaxine and bupropion in the treatment of depressive episode in patients with bipolar II disorder
por: Fakhri, Ahmad, et al.
Publicado: (2023)

Depression Treatment with Duloxetine and Reduction of Inability to Work
por: Happich, Michael, et al.
Publicado: (2012)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Combined Venlafaxine and Olanzapine Prescription in Women with Psychotic Major Depression: A Case Series
por: Ghio, Lucio, et al.
Publicado: (2011)

Venlafaxine extended release (XR) in the treatment of panic disorder
por: Kjernisted, Kevin, et al.
Publicado: (2007)

Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine
por: Maneeton, Narong, et al.
Publicado: (2013)

Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
por: Maund, Emma, et al.
Publicado: (2014)

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study
por: Zhou, Jingjing, et al.
Publicado: (2021)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h04h3f38omop9chvrqpipri8pu